Biogen Idec is the oldest independent biotechnology company in the world. It was established by a group of the world’s most accomplished biologists in 1978 in Geneva, Switzerland. Now, it has become a global organization, with offices in Japan, Brazil, Canada, Hungary, etc. The goal of Biogen Idec is to discover, develop and deliver important innovative therapies for the treatment of neurodegenerative diseases, autoimmune disorders and hemophilia to patients worldwide. Every day, countless patients benefit from its leading multiple sclerosis therapies.

 

Some of its therapies include:

- Alprolix: the first recombinant, clotting factor IX therapy with prolonged circulation

- Avonex: used as a treatment for relapsing forms of multiple sclerosis to slow the progression of disability and reduce relapses

- Fampyra: a treatment indicated to improve walking in adult patients with multiple sclerosis who have walking disabilities

- Tecfidera: an oral therapy for the treatment of relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis